In patients with advanced clear cell renal cell carcinoma (ccRCC), sitravatinib (tyrosine kinase inhibitor) has shown efficacy both alone and in combination with nivolumab (anti-PD-1). Here, the authors investigate triplet combination of sitravatinib with nivolumab and ipilimumab (anti-CTLA4) in patients with metastatic ccRCC and longitudinal single-cell transcriptomic analysis.
- Pavlos Msaouel
- Kai Yu
- Jianjun Gao
